CI
NEUTRAL
$267.11
Live
The Cigna Group · NYSE
Target $338.79
(+26.8%)
$239.51
52W Range
$350.0
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 01, 2026
Market cap
$71.35B
P/E
12.05
ROE
15.1%
Profit margin
2.2%
Debt/Equity
0.75
Dividend yield
2.34%
AI Analysis
AI-powered fundamental assessment
Confidence
80%
CI shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Mixed signals with both opportunities and risks present.
Key Strengths
Attractive valuation with P/E of 12.0
Strong ROE of 15.1%
Key Risks
Low profit margin of 2.2%
AI Fair Value Estimate
Based on comprehensive analysis
$155.19
-41.9% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
52
Moderate
75
50
50
50
35
AI Verdict
CI shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Mixed signals with both opportunities and risks present.
Key drivers: Attractive valuation with P/E of 12.0, Strong ROE of 15.1%, Low profit margin of 2.2%
Confidence
60%
Value
75/100
Rule-based valuation (P/E + Graham).
Positives
- Trades at attractive 12.0x trailing earnings.
- Trades below Graham Number.
Watchpoints
No urgent risks highlighted.
Future
50/100
Rule-based growth outlook.
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Past
50/100
Historical performance + price trend: Shares moved +20.9% over 5Y and -17.6% over 1Y.
Positives
- ROE sits at 15.1%.
Watchpoints
- Thin profit margins.
Health
50/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
35/100
Dividend policy fallback.
Positives
- Yield: 2.3%.
Watchpoints
- Weak dividend profile (Score: 35/100).
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$267.11
Analyst Target
$338.79
Upside/Downside
+26.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for CI and closest competitors.
Updated 2026-04-01
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
CI
The Cigna Group
Primary
|
+20.9% | +7.8% | -17.6% | -7.4% | -7.6% | -1.2% |
|
COR
Cencora, Inc.
Peer
|
+271.1% | +143.6% | +50.2% | +25.1% | +13.4% | +0.5% |
|
ELV
Elevance Health, Inc.
Peer
|
-7.3% | -23.6% | -17.6% | -5.1% | +13.4% | +4.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
Peer
|
+63.8% | -5.3% | +22.5% | +37.8% | -2.3% | +4.2% |
|
BDX
Becton, Dickinson and Company
Peer
|
-8.2% | -14.8% | -9.9% | +5.4% | -10.8% | -1.2% |
CI
The Cigna Group
Primary
5Y
+20.9%
3Y
+7.8%
1Y
-17.6%
6M
-7.4%
1M
-7.6%
1W
-1.2%
COR
Cencora, Inc.
Peer
5Y
+271.1%
3Y
+143.6%
1Y
+50.2%
6M
+25.1%
1M
+13.4%
1W
+0.5%
ELV
Elevance Health, Inc.
Peer
5Y
-7.3%
3Y
-23.6%
1Y
-17.6%
6M
-5.1%
1M
+13.4%
1W
+4.7%
REG
Regeneron Pharmaceuticals, Inc.
Peer
5Y
+63.8%
3Y
-5.3%
1Y
+22.5%
6M
+37.8%
1M
-2.3%
1W
+4.2%
BDX
Becton, Dickinson and Company
Peer
5Y
-8.2%
3Y
-14.8%
1Y
-9.9%
6M
+5.4%
1M
-10.8%
1W
-1.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
12.05
Forward P/E
7.99
PEG Ratio
N/A
P/B Ratio
1.69
P/S Ratio
0.26
EV/Revenue
0.34
EV/EBITDA
7.74
Market Cap
$71.35B
Profitability
Profit margins and return metrics
Profit Margin
2.17%
Operating Margin
3.53%
Gross Margin
9.3%
ROE
15.13%
ROA
4.09%
Growth
Revenue and earnings growth rates
Revenue Growth
+10.4%
Earnings Growth
-9.3%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-13.3%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.75
Moderate
Current Ratio
0.85
Weak
Quick Ratio
0.67
Poor
Cash/Share
$33.13
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$72.4B
Net Margin
1.7%
Total Assets
$157.9B
Liabilities
$116.0B
Equity
$41.7B
Debt/Equity
2.78x
Operating CF
$6.1B
CapEx
$-0.3B
Free Cash Flow
$5.8B
FCF Yield
95%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-05
$8.08
+2.5% surprise
2025-10-30
$7.83
+2.5% surprise
2025-07-31
$7.2
+0.7% surprise
Healthcare Sector Comparison
Comparing CI against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
12.05
This Stock
vs
75.44
Sector Avg
-84.0%
(Discount)
Return on Equity (ROE)
15.13%
This Stock
vs
-88.14%
Sector Avg
-117.2%
(Below Avg)
Profit Margin
2.17%
This Stock
vs
-16.28%
Sector Avg
-113.3%
(Weaker)
Debt to Equity
0.75
This Stock
vs
2.66
Sector Avg
-71.8%
(Less Debt)
Revenue Growth
10.4%
This Stock
vs
124.04%
Sector Avg
-91.6%
(Slower)
Current Ratio
0.85
This Stock
vs
4.47
Sector Avg
-81.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
CI
The Cigna Group
|
NEUTRAL | $71.35B | 12.05 | 15.1% | 2.2% | $267.11 | |
|
COR
Cencora, Inc.
|
NEUTRAL | $70.85B | 45.47 | 123.8% | 0.5% | $361.94 | Compare |
|
ELV
Elevance Health, Inc.
|
NEUTRAL | $72.42B | 13.02 | 13.2% | 2.8% | $328.11 | Compare |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
NEUTRAL | $81.68B | 18.61 | 14.9% | 31.4% | $772.64 | Compare |
|
BDX
Becton, Dickinson and Company
|
NEUTRAL | $56.67B | 25.56 | 7.0% | 8.0% | $156.41 | Compare |
CI
The Cigna Group
NEUTRAL
Mkt Cap
$71.4B
P/E
12.0
ROE
15.1%
Price
$267.11
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | NEVILLE EVERETT | Officer | Sale | 1,719 | $496,636 |
| 2026-03-02 | JONES NICOLE S. | Officer | Sale | 2,307 | $666,515 |
| 2026-02-27 | CORDANI DAVID M | Chief Executive Officer | Stock Award | 41,177 | - |
| 2026-02-27 | JONES NICOLE S. | Officer | Stock Award | 9,367 | - |
| 2026-02-27 | EVANKO BRIAN C | Officer | Stock Award | 16,215 | - |
| 2026-02-27 | KATES JAMIE G | Officer | Stock Award | 814 | - |
| 2026-02-27 | KOKA DURGA PRASAD | Officer | Stock Award | 3,177 | - |
| 2026-02-27 | NEVILLE EVERETT | Officer | Stock Award | 5,280 | - |
| 2026-02-27 | DENNISON ANN M | Chief Financial Officer | Stock Award | 5,234 | - |
| 2025-11-03 | CORDANI DAVID M | Chief Executive Officer | Purchase | 4,134 | $999,916 |
| 2025-10-06 | EVANKO BRIAN C | President | Option Exercise | 6,269 | $872,770 |
NEVILLE EVERETT
Officer
2026-03-02
1,719 shares
·
$496,636
JONES NICOLE S.
Officer
2026-03-02
2,307 shares
·
$666,515
CORDANI DAVID M
Chief Executive Officer
2026-02-27
41,177 shares
JONES NICOLE S.
Officer
2026-02-27
9,367 shares
EVANKO BRIAN C
Officer
2026-02-27
16,215 shares
KATES JAMIE G
Officer
2026-02-27
814 shares
KOKA DURGA PRASAD
Officer
2026-02-27
3,177 shares
NEVILLE EVERETT
Officer
2026-02-27
5,280 shares
DENNISON ANN M
Chief Financial Officer
2026-02-27
5,234 shares
CORDANI DAVID M
Chief Executive Officer
2025-11-03
4,134 shares
·
$999,916
EVANKO BRIAN C
President
2025-10-06
6,269 shares
·
$872,770
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
24 analysts
Bernstein
2026-03-12
Market Perform
Outperform
Piper Sandler
2026-03-03
Overweight
Overweight
Truist Securities
2026-02-17
Buy
Buy
TD Cowen
2026-02-09
Buy
Buy
RBC Capital
2026-02-06
Outperform
Outperform
Barclays
2026-02-06
Overweight
Overweight
Guggenheim
2026-02-06
Buy
Buy
Guggenheim
2026-02-02
Buy
Buy
Truist Securities
2026-01-05
Buy
Buy
Barclays
2026-01-05
Overweight
Overweight
Past News Coverage
Recent headlines mentioning CI from our newsroom.
Newest → oldest
No matching news yet.